profit from every $100 of sales.
$0$100
Profusa
$0.45-2.61% today
-99.9% in 1 year
1-year low $0.451-year high $744.00
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Profusa sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$35.8 million of profit last year.
SalesProfit
Profusa vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Profusa | No profit yet | ||
 Concentra Group Holdings Parent | 32.1× · Expensive | ||
 Hims & Hers Health | 36.0× · Expensive | ||
 Envista | 83.5× · Very expensive | ||
 Beta Bionics | No profit yet |
AI analysis
An AI analyst reads Profusa's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -9 | -6 | -5 | -28 | |
| -13 | -6 | -5 | -33 | |
| -20 | -10 | -9 | -36 | |
| -46.24 | -23.52 | -21.11 | -107.01 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1 | 2 | 3 | 4 |
| Cash | 0 | 0 | 0 | 2 |
| Total debt | 31 | 40 | 48 | 15 |
| Total liabilities | 101 | 112 | 122 | 30 |
| -100 | -110 | -119 | -27 | |
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| 20.3% | 9.3% | 7.7% | 134.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -8 | -4 | -2 | -16 | |
| – | 0 | – | 0 | |
| -8 | -4 | -2 | -16 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 0 | 0 | 1 |
Valuation
- –
- –
- –
- -0.0×
- –
- –
- –
- -5,991.3%
- -13,202.8%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- 193.7%
- 75.4%
- 154.2%
- -4,920.2%
- 107.4%
- –
Growth
- –
- –
- −686.8%
- –
- +1.0%
Financial health
- -0.4×
- -0.44
- 1,454.4%
- -10.6×
- 0.02
- 0.02
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 1%of 952
Bottom 20%of 884
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -2.05 | – | – |
| Apr 1, 2026 | -6.95 | – | – |
| Nov 19, 2025 | -0.70 | – | – |
| Aug 14, 2025 | -1.53 | – | – |
| Mar 31, 2025 | -6.21 | – | – |
| Dec 31, 2024 | -96.73 | – | – |
| Sep 30, 2024 | -96.61 | – | – |
| Jun 30, 2024 | -0.91 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/5Passes 1 of 5. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
–Not enough data
Philip Fisher
46No pass
Peter Lynch
–Not enough data
Joel Greenblatt
100Pass
Charlie Munger
54No pass
Terry Smith
49No pass
Questions about Profusa
Is Profusa a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 5 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Profusa AI analysis
What does Profusa do?
A digital-health company developing tissue-integrating biosensors (e.g. the Lumee™ Oxygen Platform) to continuously monitor body chemistry and provide AI-powered health insights, targeting chronic conditions such as diabetes and critical limb ischemia It is in Medical - Equipment & Services.
Does Profusa pay a dividend?
No. Profusa does not pay a dividend at the moment.
Is Profusa stock halal?
No. Profusa does not pass our halal screen: its debt is 5,460% of its market value, at or above the 33% limit. How we check
How has Profusa stock done over the past year?
Down 99.9% over the past twelve months, to $0.45. It traded between $0.45 and $744.00 and is 99.9% below its high.
Who are Profusa's competitors?
The largest listed companies in the same industry are Concentra Group Holdings Parent, Hims & Hers Health, Envista and Beta Bionics. The peers table on this page compares their profit, growth and price with Profusa's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.